Selenium nanoparticle benefits in NSCLCTranslational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation.
Highly relevant to lung cancer treatment
We examined the role of selenium (Se) in treating advanced non-small-cell lung cancer (NSCLC). Our research revealed that a lack of selenium leads to weakened immunity and faster tumor growth in mice. Interestingly, using selenium nanoparticles showed promising results.
These nanoparticles enhanced natural killer cell activity, boosting the immune response against cancer. In a clinical trial, patients receiving selenium nanoparticles alongside standard treatments had an impressive 83.3% response rate and complete disease control.
Overall, selenium shows potential to strengthen lung cancer therapy through immune enhancement.
Read More
We aimed to explore the potential of selenium nanoparticles synthesized from Epimedium brevicornum in combating lung cancer. Using various techniques, we characterized these nanoparticles and evaluated their effects in both lab and live models.
Although the nanoparticles were not harmful to healthy liver cells, they effectively triggered cell death in lung cancer cells, reducing tumor growth and suppressing migration.
Our findings suggest that these selenium nanoparticles could be a promising and safe avenue for lung cancer treatment.
Read More
Selenium nanoparticles may inhibit lung cancerMitochondrion-targeted selenium nanoparticles stabilized by Sargassum fusiforme polysaccharides increase reactive oxygen species-mediated antitumour activity.
High relevance for lung cancer treatment.
We examined how selenium nanoparticles, stabilized by Sargassum fusiforme polysaccharide, affect lung cancer cells. In lab tests, these nanoparticles were shown to inhibit the growth of A549 lung cancer cells and initiate cell apoptosis by increasing reactive oxygen species (ROS).
We also noticed that they impacted the mitochondria, altering important proteins linked to cancer cell survival. While animal studies showed a significant reduction in tumor growth without harming the animals, the potential for these nanoparticles as a viable treatment for non-small cell lung cancer seems promising.
Read More
We explored the effectiveness of a novel selenium nanocomposite, AANL-SeNPs, in treating lung cancer. This innovative compound, created from a natural ingredient, demonstrated significant inhibition of lung cancer cell growth in various cell lines, showing up to a 67% reduction in viability.
Furthermore, AANL-SeNPs slowed tumor growth in live models and appeared safe for normal cells. While promising, our findings indicate that although AANL-SeNPs upregulate the protein CLK2 and can enhance therapeutic response, further studies are needed to fully understand its potential.
Read More
Selenium enhances lung cancer therapySelenium enhances photodynamic therapy of C-phycocyanin against lung cancer via dual regulation of cytotoxicity and antioxidant activity.
Relevant study on lung cancer
We explored how selenium-enriched phycocyanin (Se-PC) improves photodynamic therapy for lung cancer. This combination significantly reduced the survival of lung cancer cells in mice compared to traditional treatment methods.
Our findings showed that Se-PC therapy led to a greater decrease in tumor volume and enhanced immune responses in normal tissues. Additionally, Se-PC effectively promoted cell death in cancerous cells.
Overall, while selenium has shown promise in enhancing lung cancer treatments, more research is needed to fully understand its potential benefits.
Read More